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Abstract
Sex differences in the prevalence of autoimmune diseases such as rheumatoid arthritis (RA) are
well described, but the literature is not as clear about sex differences in RA disease course and
prognosis. A recent study from a very large cross-sectional international cohort demonstrated
slightly worse levels of disease activity and function in female patients with RA, compared with men.
These findings are discussed in the context of our evolving knowledge of sex differences in the
expression of this prototypic autoimmune disease, both in terms of the actual disease activity level,
the effects that the disease has on physical function, and our ability accurately to measure these
aspects.
Commentary
Many autoimmune diseases display a striking imbalance
between the sexes, with females representing the majority
of cases. Thus, autoimmune thyroid diseases, multiple
sclerosis, and many of the rheumatological systemic
autoimmune diseases such as systemic lupus erythemato-
sus and Sjögren's syndrome affect women more often
than men (Table 1, [1-6]). This is also true for rheumatoid
arthritis (RA), where the sex ratio is typically around 3:1
[7]. The reasons for this overrepresentation of women are
not clear, but genetic (X-linked) factors and hormonal
aspects are likely to be involved [8-13].
RA is a relatively common chronic autoimmune inflam-
matory disease that affects the synovial joints, and with
time causes significant functional losses due to persistent
inflammatory activity in the joints, destruction of bone
and cartilage, and extra-articular disease manifestations.
In addition to an imbalance in the prevalence as noted
above, RA may also have an imbalance in disease course
and prognosis. Many observational studies have suggested
that, on the whole, women with RA do worse than men
with the disease [14-18]. However, this issue is not as
straightforward as it may seem. First of all, the observa-
tional data cited are not all in agreement, and some stud-
ies have not supported them. Second, because of the very
long follow-up times required, such data are always sub-
ject to various biases. Third, it is not entirely clear what
kind of 'doing worse' is most relevant. For instance, the
fact that functional outcomes are worse in female patients
may be attributed to the fact that greater muscle strength
in men allows them to compensate in a more successful
manner for functional losses, and not for differences in
the disease per se. Finally, if the disease course in women
is, indeed, more grave than in men, then the question is
raised whether this is due to a) an inherent difference in
the biology of the disease; b) a difference in the manner in
which men and women respond to therapy; or c) the ther-
apies given to men and women with the disease (Figure
1).
Recently, Sokka et al [19] published an analysis based on
an exceptionally large international cohort of RA patients,
the QUEST-RA study. This cohort of more than 6000
patients, recorded at 70 sites in 25 participating countries,
was cross-sectionally analyzed with respect to demo-
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graphics and disease activity parameters. The authors ana-
lyzed the 'core set' disease activity parameters for RA, an
internationally agreed-upon set of seven measurements
considered highly relevant for the assessment of RA [20].
These include the swollen joint count (SJC): the number
of joints that are objectively swollen as determined by the
examining physician, out of a prespecified number of
joints, usually 68 in the case of clinical trials, but reduced
to a more manageable 28 in the case of observational
studies, as was done here. The SJC is generally perceived as
a very 'objective' measure of RA disease activity. Other
core set measures include:
a) the tender joint count (TJC) where joints are
counted that are tender to palpation;
b) the patient's assessment of global disease activity
on a visual analogue scale (VAS);
c) the patient's assessment of pain by VAS – these latter
three outcomes are more obviously 'subjective' in
nature;
d) the physician's assessment of disease activity, also
usually done by VAS, and sometimes considered the
gold standard;
e) an acute-phase reactant, either the C-reactive pro-
tein or the erythrocyte sedimentation rate;
f) the health-assessment questionnaire disability
index (HAQ), which is not truly a measure of disease
activity but of function – which can be influenced by
disease activity but also by permanent damage.
A combination of four out of these seven core-set meas-
ures allows calculation of the disease activity score (DAS,
or DAS28 if SJC and TJC are based on 28 joints) which
gives a summary in one single number [21,22]. Finally,
DAS-based cut-offs can be used to define patients consid-
ered to be in remission [23,24].
In the QUEST-RA study by Sokka et al [19], it was found
that all core-set measures were higher in the female patients
(representing 79% of the patients) than in the male ones,
in apparent support of the thesis that female patients with
RA 'do worse'. However, when calculating the differences as
effect sizes, that is, asking the question how much of a differ-
ence in outcome could be attributed to the sex difference,
rather small estimates were obtained, and smallest for the
SJC. In addition, it was determined that women with only
one swollen joint or none had significantly higher levels of
subjective disease activity, and also a higher DAS28, than
men. This resulted in a lower percentage of females who
would be considered by DAS28 to be in remission. The
authors conclude that "RA disease activity measures appear
worse in women than in men, [but that] most of the gender
differences ... may originate from the measures of disease
activity rather than from RA disease activity itself."
This study is respectable in terms of its purpose and scope,
and enviable for its patient material. Nonetheless, it is not
completely clear what these data mean. Several important
aspects are touched upon, but not all can be addressed
entirely satisfactorily. The first key issue is whether there is
a sex difference in the course of RA: do women in fact 'do
worse'? On several points this study simply cannot provide
the answer. The most dramatic and definitive long-term
outcome in RA is mortality: many studies have shown that
patients with RA die mostly of the same causes as others,
but they die younger, presumably due to the long-term con-
sequences of the disease in terms of natural immunity, can-
cer surveillance, atherogenesis, etc [25-27]. No cross-
sectional study could ever demonstrate whether there is a
difference in this outcome. To the contrary, 'left-censoring',
the fact that patients who did have the worst disease might
have died before being able to contribute to the cohort,
could have attenuated any true difference between the
sexes. The second key issue has to do with physical function
in patients with RA. A sex difference in functional capacity
for patients with RA has been noted previously and was
also confirmed in this study, with women having more
functional impairment than men, but this finding is open
to different interpretations. It could be a difference in dis-
ease course, but also a difference between the ability of men
and women to compensate for any functional losses in
daily life (primarily due to the above-mentioned difference
in muscle strength, but also in bone mineral density, skin
thickness and so on). Indeed, the most widely used meas-
ure of function, the HAQ, is cross-sectionally always higher
(worse) in women.
In order to settle these and related questions more defini-
tively longitudinal studies of large cohorts of patients are
Table 1: Sex ratio in various rheumatological diseases.
Disease Female:male ratio
Sjögren's syndrome 9:1 [1]
Systemic lupus erythematosus 7:1 [2]
Rheumatoid arthritis 3:1 [3]
Systemic sclerosis 3:1 [4]
Psoriatic arthritis 1:1 [5]
Ankylosing spondylitis 1:3 [6]BMC Medicine 2009, 7:12 http://www.biomedcentral.com/1741-7015/7/12
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going to be needed. The QUEST-RA group may be well
positioned to perform such studies and we are eagerly
awaiting such data. Randomized trials, which by necessity
are more restrictive and of shorter duration, may also pro-
vide valuable insight into any true sex differences in the
course and prognosis of RA. Ultimately, such results may
impact on our understanding of autoimmune diseases as
well as on their treatment, for instance, by having sex-spe-
cific treatment algorithms if outcomes can be shown to
differ by sex and by medication.
Finally, the conclusion drawn by Sokka et al, that differ-
ences between the sexes are explained by the measurement
of the disease rather than by the disease itself, is an interest-
ing one, but perhaps not fully supported by their data. This
touches on a somewhat sensitive issue that we recently
investigated at our unit [28]. The point is this: if the 'objec-
tive' disease, that is, the amount of inflammation in the
joints, is identical, but the female patient experiences this as
'more' disease, that is, more pain, more stiffness, more gen-
eralized distress, and more functional deterioration, is it
then fair to say that the disease nonetheless is identical?
This would reflect, in my opinion, a rather limited biologi-
cal perspective. Before dwelling on that, let me clarify that
we do not yet know that this is indeed the case. However, if
it were true it should not come as a surprise: it is well
X-linked genetic factors, hormonal factors, and exposures that may be different for men and women could all influence the  prevalence of autoimmune diseases as well as their severity Figure 1
X-linked genetic factors, hormonal factors, and exposures that may be different for men and women could all 
influence the prevalence of autoimmune diseases as well as their severity. The latter aspect is, however, also influ-
enced by many more factors, including differences in the treatments given, the response to treatments, the subjective experi-
ence of the disease, and the instruments used to measure the disease. The thick arrows indicate established associations and 
the thin arrows putative associations.
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established, for instance, that given the same noxious stim-
ulus female experimental subjects experience a slightly
higher degree of physical pain; that is, the pain threshold is
lower [29-33] (this has nothing to do with the fact that
women may be, according to widely held belief, 'tougher'
when it comes to coping with pain). If that is indeed the
case, should not then our assessment of how serious the
disease really is also take into account the subjective dimen-
sion, the suffering imparted by the disease on the patient?
It would appear to me that this is particularly true for those
of us who practise (or teach the art of) medicine. After all,
when we treat our patients, we do so in order to alleviate
their suffering. And although the variability of subjective
experiences and expressions compels us to be very depend-
ent on objective data, we certainly must never forget to
whom we owe our first obligation.
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